

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bell *et al.*

Confirmation No.: 7498

Appl. No. 10/743,649

Art Unit: 1645

Filed: December 22, 2003

Examiner: R. Zeman

For: **ONCOLYTIC VIRUS**

Atty. Docket: 18003-D2

Cust. No. 31976

Information Disclosure Statement Under 37 C.F.R. § 1.97(b)(4)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on accompanying Form PTO/SB/08a be considered by the Examiner and made of record.

Disclosure of patents and other written materials

Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made or that information more material to the examination of the present patent application does not exist and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). The Examiner is specifically requested not to rely solely on the material submitted herewith.

Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

Related Applications

Applicants bring to the Examiner's attention the following patent applications: 11/685,483, filed March 13, 2007; 10/743,639, filed December 22, 2003; and 09/664,444, filed September 18, 2000.

Filing of this Information Disclosure Statement

This Information Disclosure Statement is being filed before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Therefore, no statement or fee is required. The USPTO is hereby authorized to charge any fee deficiency required to prevent abandonment of the current application or credit any overpayment to Deposit Account 50-1677.

It is respectfully requested that the Examiner initial and return a copy of the accompanying Form PTO/SB/08a and indicate in the official file wrapper of this patent application that the documents have been considered.

Respectfully submitted,

/Douglas A. Golightly/
Douglas A. Golightly
Agent for Applicants
Registration No. 51,244
240-631-2500 ext. 3342

Date: March 6, 2008